Alumis Inc. (NASDAQ:ALMS - Get Free Report) Director James Tananbaum acquired 411,764 shares of the company's stock in a transaction dated Thursday, January 8th. The stock was acquired at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the transaction, the director directly owned 5,702,536 shares of the company's stock, valued at approximately $96,943,112. This represents a 7.78% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Alumis Trading Up 7.8%
NASDAQ:ALMS opened at $21.09 on Tuesday. The firm's fifty day simple moving average is $9.54 and its 200 day simple moving average is $6.08. Alumis Inc. has a twelve month low of $2.76 and a twelve month high of $22.30. The firm has a market capitalization of $2.20 billion, a price-to-earnings ratio of -5.21 and a beta of -2.09.
Alumis (NASDAQ:ALMS - Get Free Report) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The company had revenue of $2.07 million during the quarter, compared to analysts' expectations of $3.14 million. On average, analysts predict that Alumis Inc. will post -8.51 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on the company. UBS Group reissued an "outperform" rating on shares of Alumis in a research report on Tuesday, January 6th. Oppenheimer reissued an "outperform" rating and set a $50.00 target price on shares of Alumis in a research report on Tuesday, January 6th. Guggenheim raised their price target on shares of Alumis from $18.00 to $32.00 and gave the company a "buy" rating in a report on Wednesday, January 7th. Wells Fargo & Company lifted their price target on shares of Alumis from $17.00 to $39.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 6th. Finally, Citigroup reissued an "outperform" rating on shares of Alumis in a research report on Tuesday, January 6th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $37.67.
Read Our Latest Stock Analysis on ALMS
Institutional Trading of Alumis
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Samsara Biocapital LLC raised its holdings in Alumis by 47.0% in the second quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company's stock valued at $14,404,000 after acquiring an additional 1,534,872 shares in the last quarter. Foresite Capital Management VI LLC increased its position in shares of Alumis by 1.1% in the 2nd quarter. Foresite Capital Management VI LLC now owns 4,247,670 shares of the company's stock worth $12,743,000 after purchasing an additional 45,000 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Alumis by 18.4% in the 3rd quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company's stock valued at $16,078,000 after purchasing an additional 625,404 shares in the last quarter. Trium Capital LLP lifted its position in shares of Alumis by 17.9% during the third quarter. Trium Capital LLP now owns 3,122,111 shares of the company's stock worth $12,457,000 after purchasing an additional 474,072 shares during the last quarter. Finally, Orbimed Advisors LLC acquired a new position in Alumis in the second quarter worth about $5,779,000.
Alumis Company Profile
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
